Core Viewpoint - Jiangsu Hanbang Technology Co., Ltd. has successfully listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board, with a closing price of 46.10 yuan, representing a 102.46% increase on the first day of trading [1] Company Overview - Hanbang Technology focuses on chromatography technology, integrating research and development, production, and sales, primarily serving the pharmaceutical and life sciences sectors with specialized separation and purification equipment, consumables, and technical solutions [1] - The company is controlled by Zhang Dabin, who holds 23.75% of the shares directly and has a total control of 28.94% post-IPO [1] IPO Details - The company issued 22,000,000 shares at a price of 22.77 yuan per share, raising a total of 500.94 million yuan, with a net amount of 430.67 million yuan after deducting issuance costs [4] - The total issuance costs amounted to 70.27 million yuan, with underwriting fees of 37.29 million yuan [6] Financial Performance - For the years 2022 to 2024, the company reported revenues of 481.79 million yuan, 619.01 million yuan, and 690.88 million yuan, respectively, with net profits of 38.56 million yuan, 51.50 million yuan, and 79.34 million yuan [6][7] - In the first quarter of 2025, the company achieved total revenue of 165.23 million yuan, a year-on-year increase of 19.88%, and a net profit of 11.10 million yuan, up 93.79% from the previous year [9][10] Project Funding Allocation - The raised funds will be allocated to three main projects: 1. Annual production of 1,000 units of liquid chromatography separation equipment (19.30 million yuan) 2. Construction of a chromatography separation equipment R&D center (27.11 million yuan) 3. Annual production of 2,000 units of laboratory chromatography separation and purification instruments (22.48 million yuan) [5]

特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 2 0 2 5年5月1 2日，第十八届中国科学仪器发展年会（ACCSI 2 0 2 5）在上海松江富悦大酒店盛大开幕，主题为"数智驱动·新质引领"，设置超过 1 5 0场专题报告，汇聚来自政府、科研院所、仪器企业、检测机构以及投资领域的1 8 0 0余位代表参会，会议规模再创新高，全面展现了中国科 学仪器产业在数字化转型与高质量发展背景下的创新活力。 由仪课通主办的第九届质谱人才发展论坛作为大会平行分论坛，在5月1 3日成功召开。本次论坛聚焦质谱研发、应用与人才生态、驱动行业创 新，邀请科研高校，仪器企业，应用单位相关质谱专家围绕质谱人才培养路径展开深度探讨，为推动我国质谱领域高质量发展注入新动能。 导读： 第十八届中国科学仪器发展年会于5月12日在上海成功召开，期间质谱人才发展论坛探讨质谱人才培养，聚焦产学研融合与行业发展。 论坛开场，北京大学化学与分子工程学院教授、分析测试中心副主任周江作为主持人，引领大家步入这场充满智慧与深度的交流盛会。 主 持人 ：周 江 北京大学化学与 分子工程学 ...

颁奖嘉宾与获奖 代表合影 " 3 i奖-科学仪器行业用户关注优选奖"作为仪器信息网重要产品奖项之一，已成功评选过1 7届，该奖项的评选旨在推荐出上一年度用户关注度高 的优质仪器，为用户选型采购时提供重要的参考依据。该奖项自2 0 0 7年评选以来，共选出广受用户高度关注的国内、外仪器4 0 0余台，得到广 大仪器厂商和用户的一致肯定。（ 2 0 2 4年度科学仪器行业用户关注优选奖评选说明 ） 3 i奖- 2 0 2 4年科学仪器行业用户关注优选奖"获奖名单 导读： 备受瞩目的3i奖"2024年科学仪器行业用户关注优选奖"于当晚隆重举行，在上千位行业内人士的见证下，2024年科学仪器行业用户关注优选奖获奖名单揭 晓，30台仪器获此殊荣。 特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 仪器信息网讯 2 0 2 5年5月1 2日，第十八届中国科学仪器发展年会（ACCSI 2 0 2 5）在上海富悦大酒店盛大开幕。大会吸引超1 7 0 0位科学仪器行 业相关政府领导、院士专家、仪器企业CEO、检测机构负责人、投资人、媒体记者等参会，会议规模再创 ...

特别提示 微信公众号机制调整，请点击顶部"仪 器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 关于批准发布 《家用和类似用途插头插座第31部分：装有USB电源的插座的特殊要求》 等295项推荐性国家标准和2项推荐性国家标准修改单的公告 国家市场监督管理总局（国家标准化管理委员会）批准《家用和类似用途插头插座 第3 1部分：装有USB电源的插座的 特殊要求》等2 9 5项推荐性国家标准和2项推荐性国家标准修改单，现予以公告。 国家市场监督管理总局 国家标准化管理委员会 2 0 2 5年4月2 5日 附件： 关于批准发布《家用和类似用途插头插座第3 1部分：装有USB电源的插座的特殊要求》等2 9 5项推荐性国家标准和2项 推荐性国家标准修改单的公告 (附件).wp s 国家标准公告2 0 2 5年第1 0号-关于批准发布《家用和类似用途插头插座+第3 1部分：装有USB电源的插座的特殊要求》 等2 9 5项推荐性国家标准和2项推荐性国家标准修改单的公告. p d f 点击文末"阅读原文"下载附件 AI大潮袭来，唯有学习方能不被淘汰。 全新升级版 的 AI学习资料包 免费下载：《 ...

导读： 中美经贸协定落地，科学仪器行业冰火两重天；国产替代加速崛起，"国产好仪器"再添18台，破局领跑。 特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 其中禁运、国仪定义模糊、试错成本高等数条难点直指国产替代。 前车之鉴，不以为训 。 中国人从来不会忘记历史，即使中美双边贸易恢复如初，我们也不能忘记当初禁运、加税之痛。国产仪器依然要卧薪尝 胆、韬光养晦，以免重蹈覆辙。 所幸，中美贸易协定发布的同一天，上海松江的一间会议室里， 国产仪器创新发展论坛暨成果发布如期举办 。 2 0 2 5年5月1 2日， 中美经贸会谈达成 共同降低关税的双边协定 。 公告一出， 科学仪器厂商股票涨涨跌跌， 几家欢乐几家愁。 有人说：真好，仪器采购又可以顺利进行了，终于可以 松口气了 。 禁运了，马上出来说国产仪器的春天到了。放开了，马上又唱衰国仪。停下来仔细想想，贸易条款影响了国产仪器的水 平吗？还不是好的依然好、差的依然差。这么快，就忘了疼吗？ 在5月1 3日举办的 科学仪器采购及设备更新对接座谈会 上，一位报告人列举了高校科研仪器采购的几大难点： 国外封锁 ...

Safe Harbor Statement Any statements contained in this presentation which do not describe historical facts may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding our fiscal year 2025 and beyond financial outlook, our outlook for reported revenue growth, organic revenue growth, M&A revenue growth contributions, CER currency revenue growth, margin i ...

Core Insights - Waters (WAT) reported revenue of $661.71 million for the quarter ended March 2025, reflecting a year-over-year increase of 3.9% and exceeding the Zacks Consensus Estimate of $654.63 million by 1.08% [1] - The company's EPS for the quarter was $2.25, up from $2.21 in the same quarter last year, also surpassing the consensus estimate of $2.22 by 1.35% [1] Financial Performance Metrics - Net Sales from the Water Division reached $587.30 million, exceeding the average estimate of $578.15 million by analysts, with a year-over-year increase of 4.5% [4] - Net Sales from the TA Division were $74.41 million, slightly below the estimated $77.60 million, representing a year-over-year decrease of 0.7% [4] - Product sales amounted to $400.53 million, surpassing the average estimate of $379.44 million, with a year-over-year increase of 6.5% [4] - Service net sales from TA service were $23.91 million, slightly above the average estimate of $23.34 million, showing a year-over-year decline of 1.4% [4] - Chemistry consumables generated $137.64 million in sales, close to the estimated $138.45 million, reflecting a year-over-year increase of 2.6% [4] - TA instrument systems sales were $50.50 million, below the estimated $52.82 million, with a year-over-year decrease of 0.4% [4] - Waters service net sales were $237.27 million, below the average estimate of $249.33 million, with a year-over-year increase of 0.4% [4] - Waters instrument systems sales reached $212.40 million, exceeding the average estimate of $188.18 million, with a year-over-year increase of 11.1% [4] Stock Performance - Over the past month, Waters' shares have returned +6.9%, compared to the Zacks S&P 500 composite's +11.5% change, indicating a performance that may align with the broader market in the near term [3]

Q1 2025 Earnings Call Presentation May 6, 2025 Forward-Looking Statements & Non-GAAP Financial Measures This presentation contains forward-looking statements regarding future results and events, including financial and operational guidance and projected estimates. For this purpose, any statements that are not statements of historical fact may be deemed forward-looking statements. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend," "outlook," and similar expressions (as well as ...

Core Viewpoint - Standex International Corporation reported strong financial results for the third quarter of fiscal year 2025, with record sales and operating margins, driven by acquisitions and solid performance in core businesses [1][3]. Financial Performance - Net sales increased to $207.8 million, a 17.2% year-over-year increase from $177.3 million [2]. - Operating income on a GAAP basis rose to $26.3 million, up 20.2% from $21.8 million [2]. - Adjusted operating income increased to $40.3 million, reflecting a 37.3% year-over-year growth [2]. - Net income from continuing operations on a GAAP basis was $21.9 million, a 37.6% increase from $15.9 million [2]. - Diluted EPS on a GAAP basis was $1.81, up 35.4% from $1.35 [2]. Segment Performance - Electronics segment revenue reached $111.3 million, a 38.4% increase year-over-year, with a GAAP operating income of $25.5 million [6][7]. - Engraving segment revenue decreased by 15.7% to $30.6 million, primarily due to softness in North America [10][17]. - Scientific segment revenue increased by 8.1% to $18.3 million, benefiting from the Custom Biogenic Systems acquisition [12]. - Engineering Technologies segment revenue grew by 36.2% to $27.4 million, driven by the McStarlite acquisition and organic growth [14]. - Specialty Solutions segment revenue decreased by 13.9% to $20.2 million, reflecting market softness [16]. Strategic Initiatives - The company launched three new products in the third quarter, achieving a total of 13 year-to-date, contributing over 2% to incremental sales [3]. - Standex is focused on managing costs and productivity while investing in strategic growth priorities [3]. - The acquisition of McStarlite is expected to be accretive to earnings in the first year and enhances capabilities in commercial aviation, space, and defense [3]. Outlook - For the fourth quarter of fiscal 2025, the company anticipates slightly to moderately higher revenue and adjusted operating margins, driven by recent acquisitions and pricing initiatives [4][9].

导读： 江苏汉邦科技启动招股，依托政策支持与市场需求，凭借核心技术与高研发投入，拓展产能与研发中心，推动色谱分离纯化装 备的国产替代与创新。 特别提示 微信公众号机制调整，请点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 募集资金投资项目概述 汉邦科技此次IPO募集的资金计划投资于以下项目： - 年产1 0 0 0台液相色谱系列分离装备生产项目：通过引入自动化、智能化生产设备，提高生产效率和产品质量。 - 色谱分离装备研发中心建设项目：购置先进研发设备，引进优秀人才，强化核心技术体系，提升创新能力。 江苏汉邦科技股份有限公司（股票简称"汉邦科技"，股票代码" 6 8 8 7 5 5 "）近期公布了首次公开发行股票的招股意向书 及相关文件，标志着公司正式进入招股阶段。根据发行安排，汉邦科技的网上、网下申购日定为2 0 2 5年5月7日。 政策支持与市场需求增长助力业绩提升 汉邦科技是一家专注于色谱技术研发、生产和销售的高新技术企业，其产品和服务广泛应用于制药、生命科学等领域。 作为国内最早掌握完整自主知识产权液相色谱系统技术的企业之一，汉邦科技的产品覆盖了从实验室到 ...